Torrent Pharmaceuticals has announced its unaudited consolidated financial results for the quarter and half-year ended September 30, 2025. The company reported a total revenue of ₹3302 cr for Q2 FY26, a 14% increase compared to Q2 FY25. For H1 FY26, the total revenue stood at ₹6480 cr, reflecting a 13% growth year-over-year. Key markets such as India, the United States, and Brazil have shown significant growth.
Financial Performance Q2 FY26
Torrent Pharmaceuticals’ unaudited consolidated revenue for Q2 FY26 reached ₹3302 cr, marking a 14% increase from ₹2889 cr in Q2 FY25.
Key highlights include:
- India: Revenue of ₹1820 cr, a 12% increase.
- United States: Revenue of ₹337 cr, a 26% increase.
- Germany: Revenue of ₹303 cr, a 5% increase.
- Brazil: Revenue of ₹318 cr, a 21% increase.
- Others: Revenue of ₹524 cr, a 20% increase.
Financial Performance H1 FY26
For the half-year ended September 30, 2025, Torrent Pharmaceuticals reported a total revenue of ₹6480 cr, a 13% increase compared to ₹5748 cr in H1 FY25.
Key highlights include:
- India: Revenue of ₹3631 cr, an 11% increase.
- United States: Revenue of ₹646 cr, a 23% increase.
- Germany: Revenue of ₹612 cr, a 7% increase.
- Brazil: Revenue of ₹536 cr, a 17% increase.
- Others: Revenue of ₹1055 cr, a 14% increase.
Source: BSE
